M R Veldwijk
Overview
Explore the profile of M R Veldwijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
98
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Popescu R, Savu D, Dorobantu I, Vasile B, Hosser H, Boldeiu A, et al.
Sci Rep
. 2020 Jul;
10(1):10530.
PMID: 32601333
The purpose of this study was to construct and characterize iron oxide nanoparticles (IONP) for intracellular delivery of the anthracycline doxorubicin (DOX; IONP) in order to induce tumor cell inactivation....
2.
Wendt T, Gademann G, Pambor C, von Specht H, Martin T, Baltas D, et al.
Strahlenther Onkol
. 2016 May;
180 Suppl 1:5-87.
PMID: 27137922
No abstract available.
3.
Maier P, Spier I, Laufs S, Veldwijk M, Fruehauf S, Wenz F, et al.
Gene Ther
. 2009 Oct;
17(3):389-99.
PMID: 19865182
Myelotoxicity is a dose-limiting effect of many chemotherapeutic regimens. Thus, there is great interest in protecting human hematopoietic stem cells by the transfer of drug resistance genes. The main focus...
4.
Fruehauf S, Klaus J, Huesing J, Veldwijk M, Buss E, Topaly J, et al.
Bone Marrow Transplant
. 2007 Apr;
39(12):743-50.
PMID: 17450182
High-dose chemotherapy followed by autologous blood stem cell transplantation is the standard treatment for myeloma patients. In this study, CAD (cyclophosphamide, adriamycin, dexamethasone) chemotherapy and a single dose of pegfilgrastim...
5.
Radujkovic A, Schad M, Topaly J, Veldwijk M, Laufs S, Schultheis B, et al.
Leukemia
. 2005 May;
19(7):1198-206.
PMID: 15902298
Overexpression of BCR-ABL and P-glycoprotein (Pgp) are two of the known mechanisms of imatinib resistance. As combination therapy may allow to overcome drug resistance, we investigated the effect of combination...
6.
Fruehauf S, Veldwijk M, Zeller W, Laufs S
Expert Opin Biol Ther
. 2003 Dec;
3(8):1241-51.
PMID: 14640950
Soft tissue sarcomas are a challenge for medical oncology and gene therapy. Protective and sensitising approaches that target normal and malignant tissue, respectively, both have their role for opening the...
7.
Fruehauf S, Veldwijk M, Berlinghoff S, Basara N, Baum C, Flasshove M, et al.
Cells Tissues Organs
. 2002 Nov;
172(2):133-44.
PMID: 12426490
Soft tissue sarcomas are mesenchymal tumors which respond poorly to systemic therapy. Recent studies suggest a higher response rate with an increased doxorubicin dosage. However, this was parallel with a...
8.
Veldwijk M, Fruehauf S, Schiedlmeier B, Kleinschmidt J, Zeller W
Cancer Gene Ther
. 2000 May;
7(4):597-604.
PMID: 10811478
The use of autologous hematopoietic stem cell (HSC) grafts after high-dose chemotherapy protocols may be hampered by contamination of the grafts with tumor cells. Because epithelial cells seem to be...
9.
Veldwijk M, Schiedlmeier B, Kleinschmidt J, Zeller W, Fruehauf S
Eur J Cancer
. 1999 Oct;
35(7):1136-42.
PMID: 10533460
Autologous peripheral blood progenitor cell (PBPC) grafts can be contaminated with tumour cells that potentially give rise to relapse following myeloablative therapy and PBPC transplantation. Adeno-associated virus (AAV)-based vectors produced...
10.
Schiedlmeier B, Buss E, Veldwijk M, Zeller W, Fruehauf S
Hum Gene Ther
. 1999 Jul;
10(9):1443-52.
PMID: 10395370
Hematopoietic stem cells (HSCs) are a potential target for the retrovirus-mediated transfer of chemotherapeutic drug resistance genes. For integration of the proviral DNA in the HSC genome cell division is...